BOSTON — In the ongoing fungal menin­gitis out­break tied to a Fram­ingham phar­macy, fed­eral health offi­cials now warn that anyone given an injectable drug made by the phar­macy could be at risk for infec­tion. 14,000 people were already con­sid­ered to be at risk in the out­break after receiving injectable steroids made by the New Eng­land Com­pounding Center. 15 people have died in the out­break and more than 200 people have become ill.

Health offi­cials are now telling doc­tors to warn patients of the new risks, after three new cases of infec­tion are believed to have been caused by prod­ucts other than the sus­pected steroid.

The out­break has raised ques­tions about the little known sector of “com­pounding phar­ma­cies,” which take med­ica­tions and per­son­alize them for indi­vidual patients. For a look at the industry’s reg­u­la­tions and over­sight, Morning Edi­tion host Bob Oakes spoke with a former member of the Mass­a­chu­setts Board of Phar­macy, Bill Gou­veia. He cur­rently teaches at the North­eastern Uni­ver­sity School of Pharmacy.

Read the article at WBUR →